Search

Your search keyword '"Thyssen, Jacob P"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Thyssen, Jacob P" Remove constraint Author: "Thyssen, Jacob P" Journal british journal of dermatology Remove constraint Journal: british journal of dermatology
45 results on '"Thyssen, Jacob P"'

Search Results

1. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis

4. Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort.

7. Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study.

8. The association between Staphylococcus aureus colonization on cheek skin at 2 months and subsequent atopic dermatitis in a prospective birth cohort

10. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

14. 314 Injection site reactions from an integrated analysis of phase 2 and phase 3 clinical trials of lebrikizumab treatment in moderate-to-severe atopic dermatitis

15. 322 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

17. 350 Examining the relationships among abrocitinib treatment, itch, skin pain and work and activity impairments in patients with atopic dermatitis: a mediation modelling analysis

18. 351 Examining the relationships among abrocitinib treatment, itch, skin pain and dermatology-specific quality of life in patients with atopic dermatitis: a mediation modelling analysis

19. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multi-centre `Global Healthcare Study on Psoriasis

20. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials

22. 651 - Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis.

23. Prevalence of ichthyoses in Denmark: a nationwide registry-based study.

26. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis.

27. The association between atopic dermatitis, cognitive function and school performance in children and young adults.

30. 427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies.

31. Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis.

32. Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities.

33. 424 Effect of abrocitinib vs. dupilumab on skin pain: an analysis of the phase 3 JADE COMPARE and JADE DARE trials.

35. 419 Patient satisfaction with treatments for moderate-to-severe atopic dermatitis according to degree and speed of skin and itch improvements: results from a patient survey in the United States.

36. 414 Baseline serum biomarkers do not predict dupilumab treatment response in adults with moderate-to-severe atopic dermatitis.

37. 409 Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase 3 clinical trials at 52 weeks.

38. 380 Patients maintain stable response with no or minimal fluctuations during treatment with lebrikizumab up to Week 52.

39. 395 Assessing imputation methods with the lebrikizumab clinical trial program.

40. 393 Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis.

41. 373 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: data from eight trials.

42. 322 Efficacy and safety of lebrikizumab in moderateto-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2).

43. 400 Efficacy of lebrikizumab in patients who did not achieve protocol-defined criteria for response after initial 16 weeks of therapy.

44. 381 Improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate-to-severe atopic dermatitis.

45. Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance.

Catalog

Books, media, physical & digital resources